Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jul 29 · below the Ichimoku cloud · RSI 31 · MACD below its signal · 3% above its 52-week low
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $48.1K | 0.00% | 15.41K | New | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a BLRX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for BLRX.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 12.3 | -9.0 | -18.7 | 19.6 | 37.5 | -17.5 | -9.6 | -0.7 | -16.1 | -7.7 | −21.7% | ||
| 2025 | -57.6 | -5.9 | -11.6 | 17.2 | 51.3 | -13.0 | -12.9 | -4.8 | -0.3 | -8.2 | 0.0 | -20.2 | −67.0% |
| 2024 | -24.2 | 11.8 | -15.8 | -40.2 | 11.9 | -24.0 | 38.6 | -17.7 | -16.9 | -24.1 | -26.8 | -30.0 | −86.6% |
| 2023 | 6.8 | -4.8 | 48.3 | 20.2 | 47.7 | 1.3 | -3.8 | 13.6 | 4.0 | -17.6 | -3.3 | 8.3 | +166.1% |
| 2022 | -10.8 | -16.5 | 12.5 | -28.7 | 27.9 | -17.9 | 3.1 | 15.2 | -38.8 | -8.6 | -17.6 | -15.7 | −71.1% |
| 2021 | 10.7 | 10.8 | -9.7 | 12.5 | -8.9 | -1.7 | 14.9 | -11.1 | -4.2 | 3.3 | -7.4 | -22.4 | −19.0% |
| 2020 | 4.9 | -20.3 | -29.3 | 26.3 | 15.5 | -11.9 | 32.7 | -19.8 | -9.9 | 20.7 | 15.7 | 10.0 | +12.0% |
| 2019 | 50.0 | -37.9 | 4.9 | -9.3 | -7.7 | 2.8 | -28.5 | -28.2 | -7.4 | -1.1 | 0.4 | -14.1 | −65.9% |
| 2018 | -1.8 | -6.5 | -13.0 | -8.0 | 16.3 | -4.3 | -1.1 | 5.7 | 15.1 | -34.6 | -2.9 | -35.3 | −59.6% |
| 2017 | 10.9 | 12.7 | -16.5 | -10.4 | -3.5 | 2.4 | 25.9 | -2.8 | 7.7 | -7.1 | 5.8 | -0.9 | +18.5% |
| 2016 | -20.8 | 6.8 | -7.3 | -4.9 | -2.1 | -15.8 | -2.5 | 12.8 | 30.7 | -10.4 | -1.9 | -8.9 | −29.2% |
| 2015 | 11.1 | 29.4 | -9.4 | -11.4 | 5.9 | 34.3 | -40.6 | -3.2 | 0.0 | -11.8 | -1.5 | -2.3 | −19.8% |
| 2014 | 3.9 | 3.1 | -25.9 | -9.4 | 3.0 | 0.0 | -13.9 | -6.7 | -7.8 | -9.1 | -7.9 | 25.6 | −42.3% |
| 2013 | 87.4 | -22.8 | -54.1 | 8.3 | -9.9 | -1.2 | 12.3 | 3.8 | 15.9 | 14.6 | 6.0 | 5.6 | +11.1% |
| 2012 | 25.6 | -20.6 | -9.2 | -6.6 | -13.4 | 5.2 | 10.7 | -16.3 | 16.4 | 20.2 | -12.7 | -8.3 | −20.2% |
| 2011 | -23.9 | -27.6 | 45.7 | -26.8 | 2.9 | −39.5% |
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Buy / hold / sell counts